4DMedical Allocates 88,101 Shares at $4.53 Each to Settle Consulting Fees

4DMedical Issues 88,101 Shares on 1 July 2026 to Settle Consulting Fees

4DMedical Limited has submitted an application to the ASX seeking quotation of 88,101 ordinary fully paid shares issued on 1 July 2026. These shares were not issued for cash but as payment for consulting services, representing a non-cash settlement of professional fees.

The company described the consideration as "provision of consulting fees in lieu of cash fees," assigning an estimated value of $4.53 per share. This valuation implies the consulting fees settled through the share issuance total approximately $398,897. Further details about the consulting arrangement or the consultant’s identity were not disclosed in this filing.

Valuation Basis for the $4.53 Per Share Consulting Fee Settlement

The $4.53 per share value provided is an estimate used for the purposes of the Appendix 2A filing, offering the market insight into how 4DMedical valued the shares issued in this non-cash transaction.

It is common for ASX-listed companies issuing shares in lieu of fees to establish a per-share value reflecting a recent market price or an agreed figure. The company did not specify whether this amount corresponds to a volume-weighted average price, a particular trading day’s closing price, or a negotiated rate. Interested investors may consult the Appendix 3B lodged on 26 June 2026 for additional context.

Appendix 3B Lodged on 26 June 2026 Preceded the Quotation Application

The quotation application follows an Appendix 3B submitted to the ASX on 26 June 2026 at 3:14 PM, which notified the market of the intended securities issue. The current Appendix 2A filing completes the administrative process to admit these shares to trading.

The company confirmed no further securities issuances are pending to complete this transaction, indicating this share issuance is a standalone event rather than part of a broader capital raising or staged issuance.

Total Quoted Ordinary Shares Reach 597,647,222 After Issuance

With the addition of 88,101 shares, 4DMedical’s total quoted ordinary fully paid shares outstanding will be 597,647,222. This figure represents the company’s full quoted equity base as recorded in the Appendix 2A, although the company noted that automatically generated totals may not reflect real-time issued capital if other filings are processed simultaneously by the ASX.

The incremental increase of 88,101 shares on a base of nearly 597.6 million shares equates to a dilution of less than 0.015%. For most shareholders, this has a negligible effect on ownership percentage but does slightly increase the company’s total share capital.

Overview of 4DMedical’s Capital Structure Including Options and Performance Rights

Beyond ordinary shares, 4DMedical’s capital structure includes unquoted securities such as 804,999 performance rights (4DXAX) and multiple tranches of unquoted options with varying expiry dates and exercise prices. Quoted options under code 4DXOB expiring on 1 September 2027 total 22,795,383.

Unquoted options comprise 25,456,437 options expiring on various dates and prices (4DXAG); 2,133,333 options expiring 15 March 2027 at $1.20 exercise price (4DXAJ); 1,306,100 options expiring 3 November 2027 at $1.60 (4DXAW); 4,568,275 options expiring 28 November 2029 at $0.8448 (4DXAAA); and 775,339 options expiring 30 June 2028 at $0.7534 (4DXAY). Full exercise of all outstanding options and conversion of performance rights would significantly increase the company’s share count, a factor investors should consider regarding potential dilution.

Using Non-Cash Share Issuances to Preserve Cash Reserves

Issuing shares instead of cash to settle fees is a common strategy among ASX-listed technology and medical companies to conserve cash while compensating consultants and service providers. For 4DMedical, operating in the capital-intensive medical imaging sector, preserving cash for research, development, and commercialisation is strategically important.

This share issuance avoids an outflow of approximately $398,897 in cash. Although modest relative to the company’s overall capital base, the approach reflects a broader cash management strategy typical of growth-stage technology firms. The company did not disclose its current cash balance or operating runway in this update.

Governance and Disclosure Practices Surrounding the Consulting Fee Share Issue

By issuing shares as payment for consulting services and following the ASX Listing Rules disclosure requirements through Appendix 3B and Appendix 2A filings, 4DMedical demonstrates compliance with regulatory frameworks for securities issuances outside standard placements or entitlement offers. The prior Appendix 3B filing on 26 June 2026 provided the market with advance notice of the intended share issue.

Transparency is critical in fee-for-shares arrangements, particularly as such transactions may involve related parties depending on the consultant’s identity. This filing did not specify whether the consulting fees were paid to a related party or an independent third party. Shareholders seeking further details may find additional information in upcoming periodic reports or shareholder communications.

Investor Implications of 4DMedical’s Mid-2026 Share Issuance

For current shareholders, this update confirms the completion of a previously announced securities issuance. The relatively small scale of 88,101 shares compared to nearly 598 million outstanding shares means dilution is minimal. Nonetheless, investors monitoring the company’s overall share issuance history should consider the cumulative impact of multiple small issuances alongside larger capital market transactions.

There was no clear immediate impact on the share price from this filing. Investors are likely to focus more on 4DMedical’s commercial progress in medical imaging technology, regulatory milestones, and revenue growth than on this administrative matter. No new key milestones were referenced in this update.

Background on 4DMedical’s Medical Imaging Technology for New Investors

4DMedical Limited is an Australian medical technology company specialising in lung imaging analysis. Its flagship XV Technology provides functional lung imaging that extends beyond traditional anatomical scans, enabling clinicians to assess airflow dynamics within the lungs. The technology has secured regulatory approvals in key markets and is advancing commercial rollout, particularly in the United States.

For new investors, this filing relates solely to an administrative quotation application and does not include operational updates, revenue data, clinical results, or strategic announcements. Those seeking a comprehensive understanding of 4DMedical’s financial and business status should review the company’s latest Annual Report, half-year results, and investor presentations available separately on the ASX platform.